Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide in adult short bowel syndrome with intestinal failure
2020-001202-32Phase 3Completed
- Sponsor
- VectivBio
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in short bowel syndrome (SBS) and intestinal failure (IF) comparing Apraglutide with Placebo (2 arms). Primary endpoint: Relative change from baseline in actual weekly parenteral support volume at Week 24. Started Aug 2020; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on 2020-001202-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001202-32.